<!doctype html><html><head><meta charset=UTF-8><meta name=viewport content="width=device-width,initial-scale=1"><title>GWYNU &#9897; ESTRADIOL</title><style>.table-of-contents ol { counter-reset: list-item; }
      .table-of-contents li { display: block; counter-increment: list-item; }
      .table-of-contents li:before { content: counters(list-item,'.') ' '; }

      /*
      modified from:
      School Book style from goldblog.com.ua (c) Zaripov Yura <yur4ik7@ukr.net>
      */
      pre {
             overflow-x: auto;
             white-space: pre-wrap;
             word-wrap: break-word;
        }
	pre code{
		width: 95%;
		margin: 0 auto;
		display: block;
		word-wrap: break-word;
	}
	.hljs-keyword,
	.hljs-selector-tag,
	.hljs-literal {
		  color:#005599;
		    font-weight:bold;
	}

	.hljs,
	.hljs-subst {
		  color: #3e5915;
	}

	.hljs-string,
	.hljs-title,
	.hljs-section,
	.hljs-type,
	.hljs-symbol,
	.hljs-bullet,
	.hljs-attribute,
	.hljs-built_in,
	.hljs-builtin-name,
	.hljs-addition,
	.hljs-variable,
	.hljs-template-tag,
	.hljs-template-variable,
	.hljs-link {
		  color: #2c009f;
	}

	.hljs-comment,
	.hljs-quote,
	.hljs-deletion,
	.hljs-meta {
		  color: #e60415;
	}

	.hljs-keyword,
	.hljs-selector-tag,
	.hljs-literal,
	.hljs-doctag,
	.hljs-title,
	.hljs-section,
	.hljs-type,
	.hljs-name,
	.hljs-selector-id,
	.hljs-strong {
		  font-weight: bold;
	}

	.hljs-emphasis {
		  font-style: italic;
	}

	code{
		font-size: 80%;
	}
	pre code{
		    overflow-x: auto;
		    white-space: pre;
	}
	.language-text, .language-bash{
		overflow-x: auto;
	}


    body {
	font-family: Georgia, serif;
        height:100%;
        width:100%;
	margin: 0;
    }
    img{
        max-width: 80%;
        margin: 0 auto;
        display:block;
    }
    .content{
	font-size: 24px;
        width:65%;
        margin: 0 auto;
	line-height: 1.2;
    }
    .keyword {
        font-variant: small-caps;
        font-weight: bold;
    }
    table{
        margin: 0 auto;
    }
    .outlined-block{
	    border: 1px dashed gray;
    }
    .medium-images{
	    margin: 0 auto;
	    text-align: center;
    }
    .medium-images img{
	    width: 300px;
	    max-width: 80%;
	    display: inline;
    }
    blockquote{
	    overflow-wrap: break-word;

    }
    .footnote-ref{
	    line-height:0;
	    position: relative;
	    top: 0.05em;
	    font-size: 18px;
    }
    .footnote-ref a{
	    text-decoration: none;
    }
    @media only screen and (max-width: 500px) {
	    .content{
		    width:95%;
		    font-size: 18px;
	    }
	    img{
		    max-width: 100%;
	    }
	    figure{
		    margin-inline-end: 0px;
	            margin-inline-start: 0px;
    	    }
	    ol{
		    padding-inline-start:20px;
	    }
	    pre code{
		    border-style: dashed;
		    border-width:0.01px;
		    border-color: #BDC3C7;
		    padding: 5px;
	    }
	    ul{
		    padding-inline-start: 0;
		    list-style-position: inside;
	    }
	    .footnote-ref{
		    font-size: 14px;
   	 	    line-height: 0;
		    position: relative;
		    top: 0.15em;
	    }
    }</style></head><body><div class=content><h1 id=estradiol%3A-understanding-transition>Estradiol: Understanding Transition</h1><nav class=table-of-contents><ol><li><a href=#feminizing-hormone-therapy-methods-and-breast-development>Feminizing Hormone Therapy Methods and Breast Development</a></li><li><a href=#grey-market-estradiol>Grey Market Estradiol</a><ol><li><a href=#sars-cov-2-era-work-(spring-2020---present)>SARS-CoV-2 Era Work (Spring 2020 - Present)</a><ol><li><a href=#what-makes-a-good-drug-test%3F>What makes a good drug test?</a></li><li><a href=#aptamer-based-colorimetric-sensing>Aptamer Based Colorimetric Sensing</a></li></ol></li><li><a href=#gold-nanoparticle-(aunp)-synthesis-%3Amusical_note%3A>Gold Nanoparticle (AuNP) Synthesis 🎵</a></li><li><a href=#biome-exploration-(summer-2019-winter-2020)>BIOME Exploration (Summer 2019-Winter 2020)</a><ol><li><a href=#validation-of-uv-vis>Validation of UV-Vis</a></li><li><a href=#tablet-prep.-protocol>Tablet Prep. Protocol</a></li><li><a href=#gcms-procedure-development>GCMS Procedure Development</a></li></ol></li><li><a href=#initial-quantification-project-(spring-2019)>Initial Quantification Project (Spring 2019)</a><ol><li><a href=#determination-of-estradiol-valerate-content-in-grey-market-hrt-tablets-by-uttmark%2C-tanzo-(chem-134)>Determination of Estradiol Valerate Content in Grey Market HRT Tablets by Uttmark, Tanzo (Chem 134)</a></li><li><a href=#introduction>Introduction</a></li><li><a href=#methods>Methods</a></li><li><a href=#data>Data</a></li><li><a href=#results>Results</a></li><li><a href=#conclusion-%2F%2F-future-work>Conclusion // Future Work</a></li></ol></li></ol></li></ol></nav><h2 id=feminizing-hormone-therapy-methods-and-breast-development>Feminizing Hormone Therapy Methods and Breast Development</h2><blockquote><p>“There is no current evidence that response to hormone therapy—with the possible exception of voice deepening in FtM persons—can be reliably predicted based on age, body habitus, ethnicity, or family appearance. All other factors being equal, there is no evidence to suggest that any medically approved type or method of administering hormones is more effective than any other in producing the desired physical changes.” Standards of Care for the Health of Transsexual, Transgender, and Gender Nonconforming People, WPATH 2012<sup class=footnote-ref><a href=#fn1 id=fnref1>1</a></sup></p></blockquote><p>Many trans people seek hormone replacement therapy as part of their transitioning process. Transfemme people commonly use exogenous estrogen to feminize their bodies in concert with anti-androgens that suppress masculinizing features. HRT (Hormone Replacement Therapy) has been repeatedly shown to have positive physical and psychological effects and is an established conventional medical practice<sup class=footnote-ref><a href=#fn2 id=fnref2>2</a></sup>. That said, we still do not understand enough about HRT to know if differing treatment plans result in differing physical changes<sup class=footnote-ref><a href=#fn1 id=fnref1:1>1:1</a></sup>.</p><p>We aim to investigate the relationship between differing hormone regimens used by trans feminine individuals and breast development using communal living trans archives. Using the photos posted on <a href=https://www.reddit.com/r/TransBreastTimelines/ >r/TransBreastTimelines</a> we will connect drug choices and resultant tanner stage. These data, when controlled for treatment time and age, will likely provide interesting results that hopefully can instruct trans people and medical practitioners in future medical decision making.</p><h2 id=grey-market-estradiol>Grey Market Estradiol</h2><blockquote><p>“A grey or gray market (sometimes confused with the similar term “parallel market”) refers to the trade of a commodity through distribution channels that are not authorized by the original manufacturer or trade mark proprietor. Grey market products (grey goods) are products traded outside the authorized manufacturer’s channel.” <a href=https://en.wikipedia.org/wiki/Grey_market>Wikipedia</a></p></blockquote><h3 id=sars-cov-2-era-work-(spring-2020---present)>SARS-CoV-2 Era Work (Spring 2020 - Present)</h3><p>Having relocated, lost BIOME funding and access to a GCMS or a wet-lab my options for continuing work dramatically changed.</p><p>I made the decision to focus on creating <em>cheap</em> and <em>user-friendly</em> drug tests for estradiol (and possibly testosterone). <a href="https://open.spotify.com/track/1BIbxPcsSNOzXXDKawSwCi?si=XyvKcsCwT_KVExyeMBdFQw">🎵</a></p><p>My plan is to synthesize gold nanoparticles, and then use dna aptamers to modulate their aggregation to produce a color change upon introduction of Estradiol/Testosterone.</p><h4 id=what-makes-a-good-drug-test%3F>What makes a good drug test?</h4><h4 id=aptamer-based-colorimetric-sensing>Aptamer Based Colorimetric Sensing</h4><p>On 05/16/2020, I ordered 100nmols of the 35nt aptamer from <a href="https://pubs.acs.org/doi/full/10.1021/acs.analchem.5b00335?src=recsys">this paper on estradiol aptamers</a> which I call Alsa1535. It arrived 05/22/2020.</p><pre><code class=language-nucleic>Alsa1535: 5'- AAG GGA TGC CGT TTG GGC CCA AGT TCG GCA TAG TG -3'
</code></pre><p>On 05/27/2020, I was able to confirm that Alsa1535 binds to estradiol valerate and not just estradiol with impressive linearity (R<sup>2</sup>=0.9975):</p><figure><img src=./estradiol/05272020-e2-additions-curve.png alt=""><figcaption><a href=./estradiol/COVID-Era-Work.html>How I made this graph</a></figcaption></figure><figure><img src=./estradiol/estradiolValerateTitrationLinearFit.png alt=""><figcaption><a href=./estradiol/COVID-Era-Work.html>How I made this graph</a></figcaption></figure><p>The results <em>cannot</em> be in any major part attributed to the absorption of estradiol valerate alone:</p><figure><img src=./estradiol/estradiol-valerate-abs.png alt=""><figcaption><a href=./estradiol/COVID-Era-Work.html>How I made this graph</a></figcaption></figure><h3 id=gold-nanoparticle-(aunp)-synthesis-%3Amusical_note%3A>Gold Nanoparticle (AuNP) Synthesis <a href="https://open.spotify.com/track/1TWNKyNQOBfNUkWWs7FooF?si=Rv9AavwQQbiKFNgX93jZcQ">🎵</a></h3><p>My protocol is based on <a href=https://sci-hub.tw/https://www.nature.com/articles/nprot.2006.38>this paper from Nature</a> <a href="https://pubs.acs.org/doi/full/10.1021/acs.analchem.5b00335?src=recsys">and this paper from ACS</a> and necessarily excludes some steps (eg. pre-treatment of glassware with aqua regia) due to the limitations of working out of my baby brothers room. It, and my revisions can be found <a href="">in this github repository</a>.</p><figure><img src=./estradiol/AuNP-Synthesis-05192020.png alt=""><figcaption>Initial Gold Nanoparticle Synthesis 05/19/2020: Left is HAuCl4 refluxing, middle is directly after addition of Sodium Citrate and the right follows after 15m of refluxing</figcaption></figure><p>The resulting concentration comes out to be 9.8nM (calculation via the Beer-Lambert law). In calculating the concentration, I noticed an interesting absorption spectrum for the raw nanoparticles:</p><figure><img src=./estradiol/rawAuNPwithandwithoutAptamer.png alt=""><figcaption><a href=./estradiol/COVID-Era-Work.html>How I made this graph</a></figcaption></figure><h3 id=biome-exploration-(summer-2019-winter-2020)>BIOME Exploration (Summer 2019-Winter 2020)</h3><blockquote><p>“BIOME is a student organization dedicated to providing open space for anyone interested in pursuing bioengineering and biology inspired projects.” <a href=https://biome.bio>BIOME</a>.</p></blockquote><p>After the initial quantification project, I applied for and received a project grant from <a href=https://biome.bio>BIOME</a> for continued exploration. The original application timeline and budget are available <a href=BIOME-GANTT-CHART-PROJECT-MILESTONES-06212019.xlsx>here</a>. Like many projects the initial timeline was <em>far</em> too ambitious.</p><p>The funded goals were:</p><ul><li>Validation of UV-Vis as a cheaper alternative to GCMS</li><li>A parallelizable / fast preparation protocol for tablets with varying coatings, sizes and shapes</li><li>Validation and generation of a sub 15 minute GCMS procedure for general purpose quantitation of estradiol in samples</li></ul><h4 id=validation-of-uv-vis>Validation of UV-Vis</h4><figure><img src=./estradiol/biome-uv-vis-attempt3a.png alt=""></figure><p>UV-Vis was more difficult to get consistent accurate results than previous experiments would suggest. On top of that, prepping UV-Vis samples was a hassle - there were so many steps, and each sample had to be run manually without batching.</p><figure><img src=./estradiol/biome-uv-vis-attempt1.png alt=""></figure><p>Eventually, I got consistently high R<sup>2</sup> values (~0.93-0.97 range) but I kept getting strange nonlinear like responses that set me on edge. At this point, I set UV-Vis aside because there was a) a distinct lack of faith in my data, b) no way the procedures I was using would scale to 100s of samples and c) little hope for a frameshift change in the way samples would need to be prepped.</p><figure><img src=./estradiol/biome-uv-vis-attempt2.png alt=""></figure><figure><img src=./estradiol/biome-uv-vis-attempt3b.png alt=""><figcaption>Is this… a non linear response? 👀</figcaption></figure><p>As time passed, I began to forget the pain of sample prep and again became curious about the source of the non-linearities of my data. Foreshadowing of times to come? Possibly.</p><figure><img src=./estradiol/non-linear-or-maybe-not.png alt=""></figure><h4 id=tablet-prep.-protocol>Tablet Prep. Protocol</h4><p>Tablet preparation is important. I quickly realized that, if I’m going to run 100s of samples, I can’t use my original procedure of:</p><ul><li>Weight tablet</li><li>Powder pill in mortar and pestle</li><li>Weigh by transfer produced powder (~80% transfer is average)</li><li>Wash and dry mortar and pestle</li></ul><p>it simply was too time consuming and rife with potential human error. None of the preparation methods worked at fully dissolving all tablets - with sugar (sucrose) coated tablets being the hardiest of them all.</p><figure><img src=./estradiol/pill-biome-dissolve-a.jpg alt=""><figcaption>Halving and shaking at room temp for 36 hours</figcaption></figure><figure><img src=./estradiol/pill-biome-dissolve-b.jpg alt=""><figcaption>Halving and shaking with heat (50C) for 36 hours</figcaption></figure><figure><img src=./estradiol/pill-biome-dissolve-c.jpg alt=""><figcaption>Quartering and shaking with heating (50C) for 36 hours</figcaption></figure><h4 id=gcms-procedure-development>GCMS Procedure Development</h4><p>My lab notes:</p><p><a href=./estradiol/Silylation-and-Methanol-as-an-Alternative-GC-Solvent-(W2-Winter-2020-BIOME).pdf>Silylation and Methanol as an Alternative GC Solvent</a></p><p><a href=./estradiol/Mixed-Solvent-Silylation-and-Further-GCMS-Method-Development-(Winter-2020-BIOME).pdf>Mixed Solvent Silylation &amp; Further GCMS Method Development</a></p><p>And <a href=./estradiol/10212020-Lab-Notes.pdf>Various</a> <a href=./estradiol/oct21-data.zip>other</a> <a href=./estradiol/11092020-Lab-Notes.pdf>files</a> that are less organized and likely useless to anyone but me.</p><figure><img src=./estradiol/estrogen-test-kit-initial-idea.png alt=""></figure><h3 id=initial-quantification-project-(spring-2019)>Initial Quantification Project (Spring 2019)</h3><p>In Spring of 2019 I was enrolled in an <a href="https://explorecourses.stanford.edu/search?view=catalog&amp;q=CHEM+134+Analytical+Chemistry+Laboratory&amp;academicYear=20142015">Analytical Chemistry Laboratory</a> which had a project component (which was the best part of the class imo). I, along <a href=https://www.researchgate.net/profile/Julia_Tanzo>Julia Tanzo</a> worked on developing a quick and versatile method of quantitation of Estradiol in grey market tablets.</p><p>Below is the content we presented at the end of the class. The original poster is also available as a pdf <a href=./estradiol/Chem-134-Final-Project_(uttmark-tanzo,2019).pdf>poster</a>.</p><p><strong><em>Warning:</em> I am unable to replicate the analysis presented in this poster. See <a href=./estradiol/CHEM-134-Validation.html>this page</a> for details. In short, there is an off-by-ten discrepancy that I do not have an explanation for. My partner had the flu and we only had a week to create the method and collect data - please think carefully about making conclusions from these data.</strong></p><p>After completing this project, I found <a href=https://doi.org/10.1590/S0100-40422010000400040>this paper</a> which also deals with UV quantification of estradiol.</p><h4 id=determination-of-estradiol-valerate-content-in-grey-market-hrt-tablets-by-uttmark%2C-tanzo-(chem-134)>Determination of Estradiol Valerate Content in Grey Market HRT Tablets by Uttmark, Tanzo (Chem 134)</h4><h4 id=introduction>Introduction</h4><ul><li>Estradiol is a feminizing drug used in Hormone Replacement Therapy (HRT) (with a variety of prodrugs<sup class=footnote-ref><a href=#fn3 id=fnref3>3</a></sup>, one of which is Estradiol Valerate which we consider here)</li><li>Hormone Replacement Therapy (HRT) is a regimen involving the administration of “sex hormones” for, among other things, aligning secondary sexual characteristics, mental health benefits and increased life expectancy.</li><li>Even for individuals that have access to conventional healthcare and are able to obtain prescriptions for feminizing HRT related drugs, injectable pro-estrogens have experienced multiple shortages in American and European pharmacies<sup class=footnote-ref><a href=#fn4 id=fnref4>4</a></sup>. These factors, among many others, have driven many transgender individuals by choice or not to use grey market alternatives<sup class=footnote-ref><a href=#fn5 id=fnref5>5</a></sup>.</li><li>No investigation or organized effort has ever considered the purity or variability in grey market HRT drugs<sup class=footnote-ref><a href=#fn6 id=fnref6>6</a></sup>.</li></ul><p>We aimed to fill this research and humanitarian need by looking at tablet Estradiol Valerate purchased from an easily accessible venue (eBay) and by developing a general purpose procedure. Here, we determined how much Estradiol Valerate was contained in our samples, the deviation from the reported amount and the variance in these measures across tablets.</p><figure><img src=./estradiol/estradiol-molecule-134.png alt=""><figcaption>Estradiol Valerate</figcaption></figure><p>Estradiol valerate is a prodrug metabolized by enzymatic hydrolysis into the fatty acid (shown in blue) and Estradiol (shown in black) the active component in feminizing HRT</p><h4 id=methods>Methods</h4><p>Progynova tablets presumably containing estradiol valerate were purchased via eBay from gtxl7863 (a now shutdown seller, eBay does not permit the selling of pharmaceuticals) after a brief interview with seven (7) trans individuals who had, or who knew someone that had, procured HRT outside of a doctors prescription to confirm eBay was a reasonable venue for realistic analysis. Each tablet was powdered and dissolved in methanol (methanol and tablet quantification via weighing by difference). The samples were then sonicated at 60℃ for 36 hours to completely dissolve the tablets before filtering through a 20μm filter to remove any debris. The samples were then analyzed primarily via GC MS for quantification and secondarily via UV/Vis and IR spectroscopy to identify future quantification avenues. Samples were run on an Agilent J&amp;W DB-5ht nonpolar column ((5%-phenyl)-methylpolysiloxane, 30m, 0.25 mm. 0.10 µm, 7 inch cage) with a general purpose method consisting of a 7 minute hold at 160℃, a ramp to 260℃ at 10℃/min to hold for 4 minutes and a 10℃/min ramp to 300℃.</p><figure><img src=./estradiol/packaging-134.png alt=""><figcaption>Packaging (external)</figcaption></figure><figure><img src=./estradiol/packaging2-134.png alt=""><figcaption>Packaging (internal)</figcaption></figure><figure><img src=./estradiol/pill-134.png alt=""><figcaption>Tablet held for size reference</figcaption></figure><h4 id=data>Data</h4><p>This section was not on the original poster. As mentioned above, my off-by-ten attempt to replicate the calculations done here can be seen <a href=./estradiol/CHEM-134-Validation.html>here</a>.</p><table><thead><tr><th>Pill</th><th>GCMS Area</th><th>Concentration (mg/mL)</th><th>Powdered Pill in Sample (g)</th><th>Initial Pill Weight</th><th>Estimated Estradiol Valerate in Pill (mg)</th><th>Confidence Interval (mg)</th></tr></thead><tbody><tr><td>1</td><td>6761580.64</td><td>0.10318</td><td>0.0977</td><td>0.1445</td><td>1.52694</td><td>0.05206</td></tr><tr><td>2</td><td>6107657.14</td><td>0.09371</td><td>0.1093</td><td>0.1395</td><td>1.19717</td><td>0.04493</td></tr><tr><td>3</td><td>6153476.16</td><td>0.09437</td><td>0.0951</td><td>0.1313</td><td>1.30907</td><td>0.0486</td></tr><tr><td>4</td><td>6179034.76</td><td>0.09474</td><td>0.1017</td><td>0.136</td><td>1.27196</td><td>0.04707</td></tr><tr><td>5</td><td>6975218.59</td><td>0.10627</td><td>0.1207</td><td>0.1394</td><td>1.22867</td><td>0.04065</td></tr><tr><td>6</td><td>7355210.59</td><td>0.11177</td><td>0.1204</td><td>0.1355</td><td>1.26107</td><td>0.03961</td></tr><tr><td>7</td><td>8286964.05</td><td>0.12527</td><td>0.1069</td><td>0.1288</td><td>1.51011</td><td>0.04241</td></tr><tr><td>8</td><td>10433601.48</td><td>0.15635</td><td>0.1286</td><td>0.1428</td><td>1.74431</td><td>0.03909</td></tr><tr><td>9</td><td>7987559.16</td><td>0.12093</td><td>0.1242</td><td>0.1409</td><td>1.37337</td><td>0.03993</td></tr><tr><td>10</td><td>7206660.82</td><td>0.10962</td><td>0.1267</td><td>0.1361</td><td>1.17814</td><td>0.03781</td></tr></tbody></table><p>The raw data is also available <a href=./estradiol/134-data-raw.csv>here</a> as a csv file.</p><h4 id=results>Results</h4><p>We quantified ten estradiol valerate tablets. While their reported estradiol valerate content was 1 mg/tablet, we instead found their estradiol valerate content to be on average 1.36 mg/tablet with a variance of 0.0295 mg<sup>2</sup>. We identified no correlation (R<sup>2</sup>=0.25) between either tablet weight and estradiol content or peak area. See below for tablet quantification distribution.</p><figure><img src=./estradiol/tablet-quant-134.png alt=""><figcaption>Tablet quantification with 95% confidence error intervals</figcaption></figure><figure><img src=./estradiol/external-standard-134.png alt=""><figcaption>External estradiol standard Curve (GCMS), R<sup>2</sup>=0.9905</figcaption></figure><figure><img src=./estradiol/ei-fragmentation-134.png alt=""><figcaption>Estradiol valerate’s electron ionization fragmentation (M+ m/z = 356.3)</figcaption></figure><figure><img src=./estradiol/ev-peak-134.png alt=""><figcaption>Estradiol chromatogram peak (RT = 17.507 min, M+ m/z = 272.2)</figcaption></figure><figure><img src=./estradiol/estradiol-peak-134.png alt=""><figcaption>Estradiol valerate chromatogram peak (RT = 22.708 min, M+ m/z = 356.3)</figcaption></figure><p>We also briefly explored UV/Vis and IR spectrometry as an alternative analysis method as it is both cheaper and faster than GCMS. While IR showed no peaks for quantification of an estradiol standard, UV/Vis spectroscopy did, with a peak at 289 nm having a linear dependence on solution concentration (n=4, R2=0.9958). However, the same absorbance peak was not identified in estradiol valerate nor did we have enough estradiol samples to analyze a real world example for a proof-of-concept.</p><figure><img src=./estradiol/uv-vis-quant-134.png alt=""><figcaption>UV/Vis peaks at varying concentrations of estradiol standard</figcaption></figure><h4 id=conclusion-%2F%2F-future-work>Conclusion // Future Work</h4><p>We have found the estradiol valerate content of grey market HRT tablets to greatly differ from their reported values. While it is still unclear as to the effects of varying dosage on transitioning, it is known that varying estradiol supplements in postmenopausal women increases risk for deep vein thrombosis which is not uncommonly fatal<sup class=footnote-ref><a href=#fn7 id=fnref7>7</a></sup>. For these reasons, it is very important that further work is done to determine the risk associated with “DIY” HRT. We have found that UV/Vis spectroscopy is a promising avenue for continuing quantification of different grey market HRT alternatives that contain estradiol (but not estradiol valerate) without the cost and time associated with GCMS.</p><p><strong>This class project was funded by Stanford University and any generated IP is open sourced under a [LICENSE].</strong></p><hr class=footnotes-sep><section class=footnotes><ol class=footnotes-list><li id=fn1 class=footnote-item><p>The World Professional Association for Transgender Health “Standards of Care for the Health of Transsexual, Transgender, and Gender Nonconforming People” vol 7 (2012) [<a href=http://www.wpath.org/media/cms/Documents/SOC>www.wpath.org/media/cms/Documents/SOC</a> v7/Standards of Care_V7 Full Book_English.pdf](<a href=https://www.wpath.org/media/cms/Documents/SOC>https://www.wpath.org/media/cms/Documents/SOC</a> v7/Standards of Care_V7 Full Book_English.pdf) <a href=#fnref1 class=footnote-backref>↩︎</a> <a href=#fnref1:1 class=footnote-backref>↩︎</a></p></li><li id=fn2 class=footnote-item><p>Unger, Cécile A. “Hormone therapy for transgender patients.” Translational andrology and urology vol. 5,6 (2016): 877-884. doi:10.21037/tau.2016.09.04 <a href=#fnref2 class=footnote-backref>↩︎</a></p></li><li id=fn3 class=footnote-item><p>B. Duumlsterberg, M. Schmidt-Gollwitzer, and M. Huumlmath-semicolonmpel, “Pharmacokinetics and biotransformation of estradiol valerate in ovariectomized women,” Hormone Research, vol. 21, no. 3, pp. 145–154, 1985 <a href=#fnref3 class=footnote-backref>↩︎</a></p></li><li id=fn4 class=footnote-item><p>T. U. S. F. D. Administration, “Fda drug shortages.” <a href="https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Estradiol%20Valerate%20Injection,%20USP&amp;st=c">https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Estradiol Valerate Injection, USP&amp;st=c</a> <a href=#fnref4 class=footnote-backref>↩︎</a></p></li><li id=fn5 class=footnote-item><p>C. Nast, “How an estrogen shortage is making life hell for trans femmes.” <a href=https://www.them.us/story/estrogen-shortage-estradiol-valerate>https://www.them.us/story/estrogen-shortage-estradiol-valerate</a>. <a href=#fnref5 class=footnote-backref>↩︎</a></p></li><li id=fn6 class=footnote-item><p>Coleman et, al. “Standards of care for the health of transsexual, transgender, and gender-nonconforming people, version 7,” International Journal of Transgenderism, vol. 13, pp. 165–232, Aug. 2012 <a href=#fnref6 class=footnote-backref>↩︎</a></p></li><li id=fn7 class=footnote-item><p>M. Townsend, H. Jaffer, and L. Goldman, “Adverse health outcomes in transgender people,” Canadian Medical Association Journal, vol. 189, pp. E1046–E1046, Aug. 2017 <a href=#fnref7 class=footnote-backref>↩︎</a></p></li></ol></section></div></body></html>